I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Combination antiretroviral therapy (ART), also known as highly active ART, is the mainstay of management of patients with human immunodeficiency virus (HIV) infection.\[[@ref1]\] Antiretroviral (ARV) therapy is potent, convenient, and usually well tolerated, capable of reducing HIV blood concentration to undetectable values within a few weeks from treatment initiation and of inducing a robust and sustained CD4 T-cell gain.\[[@ref2]\] At present, all international guidelines recommend treatment of all HIV-positive patients irrespective of their CD4 count.\[[@ref3][@ref4][@ref5][@ref6]\] According to latest recommendations, early initiation of antiretroviral therapy (ART) is needed to reduce morbidity and mortality from HIV infection and to reduce HIV transmission.\[[@ref7]\] It is now strongly evident from various randomized control trials that initiating ART at higher CD4 count entails individual benefit in addition to population benefit by preventing HIV transmission to non-HIV-infected partners.\[[@ref8][@ref9]\] The major challenge to the success of therapy is the emergence of adverse drug reactions (ADRs) related to ART that lead to modification of ART and also affect treatment adherence.\[[@ref10][@ref11][@ref12][@ref13]\] ART-associated ADRs may range from acute and potentially life threatening to chronic and insidious conditions. Serious life-threatening reactions such as hypersensitivity reaction, symptomatic hepatotoxicity, and severe cutaneous drug reactions warrant immediate discontinuation of ARV drugs and switching over to alternative regimen without overlapping toxicities. The non-life-threatening toxicities such as urolithiasis and renal tubulopathy are addressed by substituting the presumed causative ARV agent without interrupting the ART. For chronic non-life-threatening adverse events such as dyslipidemia, either switching the potentially causative ARV with another ARV agent or managing the adverse event by pharmacological or nonpharmacological interventions is done. These management strategies for adverse events must be individualized for a specific patient.\[[@ref14]\] The goal of the present study was to evaluate the frequency and nature of adverse events in HIV-positive patients undergoing ART at ART center in Government Medical College, Amritsar.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

This was a prospective observational cohort study conducted at ART center, Government Medical College, Amritsar. The study was conducted from January 2017 to July 2017. The cohort included both ART-naïve and ART-experienced HIV-positive patients undergoing treatment at ART center. The sample size was determined by the prevalence of ADRs due to ART in a study conducted at a tertiary care center in East India, by taking critical value at 95% confidence interval and degree of precision 0.05.\[[@ref15]\] The data were collected from the HIV-positive patients reporting to ART center. ADRs were diagnosed and classified as per the National AIDS Control Organization (NACO) guidelines, based on clinical presentations and laboratory investigations. Among all patients who received ART regimens and followed up as per the NACO guidelines, those presented with confirmed ADRs diagnosed on the basis of clinical examinations and laboratory investigations were consecutively recruited in the study. Patients were followed up monthly as a part of regular treatment.

The primary outcome of the study was to assess the frequency and nature of adverse events in HIV-positive patients undergoing ART. Immunological status was assessed by CD4 counts. Informed consent was taken from each patient enrolled in the study, and approval from the Institutional Ethics Committee, Government Medical College, Amritsar, was obtained.

Inclusion criteria {#sec2-1}
------------------

To assess the ART-related side effects, all HIV male, female, and transgender participants above 18 years were included in the study. Both ART-naïve and ART-experienced patients currently undergoing treatment were recruited. Only those patients with ADR confirmed based on clinical presentation and diagnostic parameters were considered for recruitment in the study.

Exclusion criteria {#sec2-2}
------------------

All HIV-positive patients \<18 years were excluded from the study. Current pregnancy or lactating females were not included in the study. The HIV-positive patients not taking ART were not included in the study.

The diagnosis of HIV positivity was based on serological test and enzyme-linked immunosorbent assay, by detecting HIV-specific antibody. The patients were assessed for clinical signs and symptoms of ADRs by taking history and performing complete physical examination. Patients were further categorized according to the World Health Organization (WHO) clinical staging \[[Annexure 1](#APP1){ref-type="app"}\]. The laboratory parameters considered for the evaluation of ADRs were complete blood count, liver function test, renal function test, lipid profile, urine routine and microscopic examination, and CD4 count to assess the immunological status of the patients. Some imaging tools such as chest X-ray and ultrasound whole abdomen were considered to assess the findings, when needed. The causality of reported ADRs assessed according to the WHO guidelines.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

The present study enrolled 350 HIV-positive patients who presented to ART center from January 2017 to July 2017. Out of 350 patients, 84 with confirmed ADRs who met inclusion and exclusion criteria were considered for final analysis. Out of 84 HIV-positive patients recruited, 45 and 39 were male and female, respectively \[[Figure 1](#F1){ref-type="fig"}\].

![Gender distribution](JGID-11-73-g001){#F1}

Patients who presented with ADRs were on one of the four ART regimens: tenofovir + lamivudine + efavirenz (TLE), zidovudine + lamivudine + nevirapine (ZLN), zidovudine + lamivudine + atazanavir (ZL + ATZr), tenofovir + lamivudine + atazanavir (TL + ATZr), and zidovudine + lamivudine + efavirenz (ZLE). Patients who developed ADR were mostly on TLE regimen (59.52%) \[[Figure 2](#F2){ref-type="fig"}\].

![Antiretroviral therapy regimens](JGID-11-73-g002){#F2}

Central nervous system (CNS) (19.05%)-, renal (14.29%)-, and immune reconstitution inflammatory syndrome (IRIS) (14.29%)-related ADRs were mostly reported. Other ADRs included drug-induced hyperbilirubinemia (9.52%), anemia (8.33%), peripheral neuropathy (8.33%), skin reactions (7.14%), lipodystrophy (4.76%), hepatitis (4.76%), gynecomastia (3.57%), osteoporosis (2.38%), myalgia (1.19%), atypical diarrhea (1.19%), and joint pain (1.19%) \[[Figure 3](#F3){ref-type="fig"}\].

![Adverse drug reaction reported](JGID-11-73-g003){#F3}

Severity of ADRs was assessed as 73.81% mild, 11.90% moderate, and 14.29% severe grades \[[Figure 4](#F4){ref-type="fig"}\].

![Severity of adverse drug reactions](JGID-11-73-g004){#F4}

The causality assessment according to the WHO guidelines revealed 19.05% probable and 80.95% possible ADR categories \[[Figure 5](#F5){ref-type="fig"}\], with chi-square = 8.656 and *P* = 0.07 \[[Table 1](#T1){ref-type="table"}\]. Figure 5World Health Organization causality assessment

###### 

WHO causality assessment

  WHO causality categories   WHO causality assessment   Percentage   *χ*^2^, *P*                        
  -------------------------- -------------------------- ------------ ------------- --- --- ---- ------- -------------
  Probable                   7                          3            1             3   2   16   19.05   8.656, 0.07
  Possible                   43                         17           0             4   4   68   80.95   

TLE: Tenofovir + lamivudine + efavirenz, ZLN: Zidovudine + lamivudine + nevirapine, ZL + ATZr: Zidovudine + Lamivudine + Atazanavir, TL + ATZr: Tenofovir + Lamivudine + Atazanavir, ZLE: Zidovudine + Lamivudine + Efavirenz, WHO: World Health Organization

Among these patients, majority had CD4 count \< 200/μl (47.62%) at the initiation of ART and between 200 and 499/μl when they reported with ADRs. Most of the patients were asymptomatic and found to be in the WHO clinical stage I at the initiation of ART (51.19%). Patients were mostly observed to be in WHO clinical stage I even when they developed ADRs (77.38%). However, *P* values for CD4 count and WHO clinical stage, at baseline and during episode of ADRs, were insignificant \[[Table 2](#T2){ref-type="table"}\]. Most of the patients required no post-ADR intervention (73.81%). However, 15.48% required substitution of therapy \[[Table 2](#T2){ref-type="table"}\].

###### 

Patients characteristics in different treatment groups

  Patients characteristics               Treatment regimen (TLE)   Treatment regimen (ZLN)   Treatment regimen (ZL + ATZr)   Treatment regimen (TL + ATZr)   Treatment regimen (ZLE)   Percentage   *χ*^2^, *P*
  -------------------------------------- ------------------------- ------------------------- ------------------------------- ------------------------------- ------------------------- ------------ ---------------
  Number of patients                     50                        20                        1                               7                               6                                      
  Gender                                                                                                                                                                                            
   Male                                  24                        13                        0                               3                               5                         53.57        5.29, 0.259
   Female                                26                        7                         1                               4                               1                         46.43        
  CD4 cell count categories (baseline)                                                                                                                                                              
   \>500                                 4                         1                         0                               0                               1                         7.14         8.208, 0.413
   200-499                               27                        6                         0                               2                               3                         45.24        
   \<200                                 19                        13                        1                               5                               2                         47.62        
  CD4 cell count categories (at ADR)                                                                                                                                                                
   \>500                                 11                        5                         0                               0                               1                         20.24        8.502, 0.386
   200-499                               24                        13                        1                               5                               5                         57.14        
   \<200                                 15                        2                         0                               2                               0                         22.62        
  WHO clinical stage (baseline)                                                                                                                                                                     
   I                                     27                        7                         0                               4                               5                         51.19        14.590, 0.265
   II                                    3                         4                         0                               0                               0                         8.33         
   III                                   13                        8                         1                               3                               0                         29.76        
   IV                                    7                         1                         0                               0                               1                         10.71        
  WHO clinical stage (at ADR)                                                                                                                                                                       
   I                                     34                        19                        0                               6                               6                         77.38        20.738, 0.054
   II                                    7                         0                         1                               0                               0                         9.52         
   III                                   3                         1                         0                               1                               0                         5.95         
   IV                                    6                         0                         0                               0                               0                         7.14         
  Types of ADRs                                                                                                                                                                                     
   Anemia                                0                         3                         0                               1                               3                         8.33         
   Atypical diarrhea                     1                         0                         0                               0                               0                         1.19         
   CNS-related side effects              15                        1                         0                               0                               0                         19.05        
   Drug-induced hyperbilirubinemia       0                         2                         1                               3                               2                         9.52         
   Gynecomastia                          2                         0                         0                               0                               1                         3.57         
   Hepatitis                             2                         2                         0                               0                               0                         4.76         
   IRIS                                  11                        1                         0                               0                               0                         14.29        
   Joint pain                            1                         0                         0                               0                               0                         1.19         
   Lipodystrophy                         0                         4                         0                               0                               0                         4.76         
   Myalgia                               1                         0                         0                               0                               0                         1.19         
   Osteoporosis                          2                         0                         0                               0                               0                         2.38         
   Peripheral neuropathy                 1                         6                         0                               0                               0                         8.33         
   Renal derangement                     9                         1                         0                               2                               0                         14.29        
   Skin reaction                         5                         0                         0                               1                               0                         7.14         
  Severity of ADRs                                                                                                                                                                                  
   Mild                                  40                        16                        0                               3                               3                         73.81        15.106, 0.057
   Moderate                              6                         2                         0                               1                               1                         11.90        
   Severe                                4                         2                         1                               3                               2                         14.29        
  Post-ADR intervention                                                                                                                                                                             
   None                                  40                        16                        0                               3                               3                         73.81        
   Dose modify                           4                         0                         0                               0                               0                         4.76         
   Substitute                            4                         4                         1                               1                               3                         15.48        
   Switch                                1                         0                         0                               1                               0                         2.38         
   Stop                                  1                         0                         0                               2                               0                         3.57         

ADRs: Adverse drug reactions, CNS: Central nervous system, IRIS: Immune reconstitution inflammatory syndrome, WHO: World Health Organization, TLE: Tenofovir + lamivudine + efavirenz, ZLN: Zidovudine + lamivudine + nevirapine, ZL + ATZr: Zidovudine + Lamivudine + Atazanavir, TL + ATZr: Tenofovir + Lamivudine + Atazanavir, ZLE: Zidovudine + Lamivudine + Efavirenz

The mean treatment duration for the development of ADRs was 2.6 ± 2.88 (mean ± standard deviation) years. Most of the patients developed ADRs within 1 year of treatment (45.24%) \[[Table 3](#T3){ref-type="table"}\]. The mean treatment duration for development of ADRs for the patients on TLE, ZLN, ZL + ATZr, TL + ATZr, and ZLE was 1.23 ± 1.87, 4.33 ± 2.58, 2.60 ± 1.83, 6.96 ± 3.55, and 5.80 ± 0.00 years, respectively. *P* values for treatment duration for the development of ADRs were significant except for patients on ZLE regimen \[[Table 4](#T4){ref-type="table"}\].

###### 

Mean treatment duration at ADRs

  Treatment duration (year)   Number of patients   Percentage of patients   Mean treatment duration at ADRs (mean±SD)
  --------------------------- -------------------- ------------------------ -------------------------------------------
  ≤1                          38                   45.24                    2.6±2.88
  \>1-≤5                      29                   34.52                    
  \>5-≥10                     16                   19.05                    
  \>10                        1                    1.19                     

ADRs: Adverse drug reactions, SD: Standard deviation

###### 

Mean treatment duration in different treatment groups

  Treatment duration (year)   Treatment regimen (TLE)   Treatment regimen (ZLN)   Treatment regimen (ZL + ATZr)   Treatment regimen (TL + ATZr)   Treatment regimen (ZLE)
  --------------------------- ------------------------- ------------------------- ------------------------------- ------------------------------- -------------------------
  Mean±SD                     1.23±1.87                 4.33±2.58                 2.60±1.83                       6.96±3.55                       5.80±0.00
  *P*                         0.000                     0.000                     0.021                           0.019                           Nonsignificant

TLE: Tenofovir + lamivudine+efavirenz, ZLN: Zidovudine + lamivudine + nevirapine, ZL + ATZr: Zidovudine + Lamivudine + Atazanavir, TL + ATZr: Tenofovir + Lamivudine + Atazanavir, ZLE: Zidovudine + Lamivudine + Efavirenz, SD: Standard deviation

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

According to the WHO, almost 20.9 million people were receiving ART by the mid-2017.\[[@ref16]\] ADRs have been reported with all ARV drugs; however, overall benefits of viral suppression and improved immune function far outweigh the risk.\[[@ref17]\] In the present study, 84 HIV-positive patients on ART reported with ADRs during the study period of 7 months. ADRs reported in the present study are less as compared to previous studies.\[[@ref13][@ref18]\] This shows that newer ART regimens are associated with fewer and less ADRs as compared to the past.\[[@ref17]\]

In the present study, maximum ADRs were experienced by the patients on TLE regimen, which may be attributed to larger number of patients receiving this combination as first-line therapy.\[[@ref19]\] ADRs related to CNS (19.05%), renal (14.29%), and IRIS (14.29%) were mostly reported. Other system-related ADRs found were drug-induced hyperbilirubinemia (9.52%), anemia (8.33%), peripheral neuropathy (8.33%), skin reaction (7.14%), lipodystrophy (4.76%), hepatitis (4.76%), gynecomastia (3.57%), osteoporosis (2.38%), myalgia (1.19%), atypical diarrhea (1.19%), and joint pain (1.19%), as found in a prospective observational study conducted for 6 months to study ADRs in 235 AIDS patients on ART, though incidence of ADRs reported was less in this study.\[[@ref13]\]

Patients mostly experienced CNS-related ADRs such as vivid dreams, insomnia, and mild depression as most of them were on TLE regimen. Efavirenz is documented for causing CNS-related ADRs.\[[@ref17]\] In a retrospective cross-sectional observational study, conducted for 18 months to study type of ADRs and causality, severity and preventability assessment of 197 spontaneously reported ADRs found neuropsychiatric (29.44%)-related ADRs as most common followed by gastrointestinal-hepatobiliary-related ADRs (24.87%).\[[@ref20]\]

Most of the ADRs reported were of mild grade (73.81%), which required no post-ADR interventions in the form of discontinuation of therapy, dose modification, drug substitution, or switch to other regimens.\[[@ref21]\] However, moderate (11.90%) and severe grade (14.29%) ADRs required post-ADR interventions as per the NACO guidelines.\[[@ref21]\]

According to the WHO causality assessment, mostly ADRs were possible (80.95%) and rest were probable (19.05%). However, *P* value was insignificant for ADR categories. Similar results on causality assessment were obtained in a prospective observational study, conducted for a period of 6 months to study type and risk factors for ADRs due to ART in 158 patients evaluated.\[[@ref22]\]

The present study did not show any association between CD4 count and clinical staging with ADRs, while other studies have associated low CD4 count as risk factor for ADRs.\[[@ref23][@ref24]\] However, majority of the patients had CD4 count \<200/μl (47.62%) at the initiation of ART and between 200 and 499/μl when they reported with ADRs.

Most of the patients developed ADRs early in course of treatment. Treatment duration was significantly associated with ADRs in the present study, except for the patients on ZLE. In a prospective observational study conducted for a period of 1 year in 280 patients, to monitor ADRs associated with various ART regimens, most of the ADRs were observed within 6 months of initiation of therapy.\[[@ref25]\]

Limitations {#sec2-3}
-----------

The present study was conducted for a short period at a single center with a small sample size. Moreover, data for adherence were lacking that could affect ADRs due to inadequate treatment uptake. Detailed investigations could not be ordered other than routine one due to limited resource setting.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Effective ART is required for viral suppression and improvement of immune status, but risk of ADRs is also associated with it. ADRs in HIV-positive patients on ART possess a huge challenge in lifelong continuation of therapy. Regular monitoring of ADRs is important for early detection and prevention of ADRs. Low CD4 count \<200/μl at the initiation of ART and treatment duration \<1 year was found to be a predictor for ADRs. Early initiation of ART led to an improvement in immunological status, slowed progression to AIDS, and decrease in the incidence of ADRs.

Financial support and sponsorship {#sec2-4}
---------------------------------

Department of Health Research (Ministry of Health and Family Welfare), Indian Council of Medical Research (ICMR), New Delhi.

Conflicts of interest {#sec2-5}
---------------------

There are no conflicts of interest.

We would like to thank the Department of Health Research (Ministry of Health and Family Welfare), Indian Council of Medical Research (ICMR), New Delhi.

###### 

World Health Organization clinical staging of Human immunodeficiency virus disease in adults and adolescents^a^

  ------------------------------------------------------------------------------------------------------------------------------------------------
  WHO staging        Clinical features
  ------------------ -----------------------------------------------------------------------------------------------------------------------------
  Clinical Stage 1   Asymptomatic\
                     Persistent generalized lymphadenopathy

  Clinical Stage 2   Moderate unexplained weight loss (\<10% of presumed or measured body weight)\
                     Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, and pharyngitis)\
                     Herpes zoster\
                     Angular cheilitis\
                     Recurrent oral ulceration\
                     Papular pruritic eruption\
                     Fungal nail infections\
                     Seborrheic dermatitis

  Clinical Stage 3   Unexplained severe weight loss (\>10% of presumed or measured body weight)\
                     Unexplained chronic diarrhea for longer than 1 month\
                     Unexplained persistent fever (intermittent or constant for longer than 1 month)\
                     Persistent oral candidiasis\
                     Oral hairy leukoplakia\
                     Pulmonary tuberculosis\
                     Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, and bacteremia)\
                     Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis\
                     Unexplained anemia (\<8 g/dl), neutropenia (\<0.5×10^9^/l), and/or chronic thrombocytopenia (\<50×10^9^/l)

  Clinical Stage 4   HIV wasting syndrome\
                     *Pneumocystis jirovecii* pneumonia\
                     Recurrent severe bacterial pneumonia\
                     Chronic herpes simplex infection (orolabial,genital, or anorectal of\>1-month duration or visceral at any site)\
                     Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs)\
                     Extrapulmonary tuberculosis\
                     Kaposi sarcoma\
                     Cytomegalovirus infection (retinitis or infection of other organs)\
                     Central nervous system toxoplasmosis\
                     HIV encephalopathy\
                     Extrapulmonary cryptococcosis, including meningitis\
                     Disseminated nontuberculous mycobacterial infection\
                     Progressive multifocal leukoencephalopathy\
                     Chronic cryptosporidiosis\
                     Chronic isosporiasis\
                     Disseminated mycosis (extrapulmonary histoplasmosis and coccidioidomycosis)\
                     Lymphoma (cerebral or B-cell non-Hodgkin)\
                     Symptomatic HIV-associated nephropathy or cardiomyopathyRecurrent septicemia (including nontyphoidal Salmonella)\
                     Invasive cervical carcinoma\
                     Atypical disseminated leishmaniasis
  ------------------------------------------------------------------------------------------------------------------------------------------------

Source: Adapted from the WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva: World Health Organization; 2007. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/annexes/WHO_CG_annex_1.pdf. ^a^In the development of this table, adolescents were defined as 15 years or older. HIV: Human immunodeficiency virus, WHO: World Health Organization
